Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Adis is an information provider.
We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
Originator
Medical University of South Carolina; Oncovir
Developer
Abramson Cancer Center of the University of Pennsylvania; Augusta University; Bristol-Myers Squibb; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Immatics N.V.; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); New York University School of Medicine; OncoQuest; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospitals of Geneva; University of Calgary; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
Class
Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
Mechanism of Action
2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Natural killer cell stimulants; Natural killer T cell stimulants; Proto oncogene protein c rel modulators; Proto oncogene protein c-ret modulators; Toll-like receptor 3 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Phase II
Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours
Phase I/II
B-cell lymphoma; Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; HIV infections; Non-Hodgkin's lymphoma; Peritoneal cancer
Phase I
COVID 2019 infections; Liver cancer; Mesothelioma; Pancreatic cancer; Prostate cancer
No development reported
Acute myeloid leukaemia; Anaplastic astrocytoma; Chronic myelomonocytic leukaemia; Cytomegalovirus infections; Glioma; Influenza virus infections; Myelodysplastic syndromes; Smallpox
Most Recent Events
03 Oct 2022
Parker Institute for Cancer Immunotherapy in collaboration with Nektar Therapeutics completes its phase I PORTER trial in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA (IM) (NCT03835533)
28 Jul 2022
No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IM, Injection)
06 May 2022
Icahn School of Medicine at Mount Sinai and Oncovir, completes a phase I trial in Prostate cancer (Neoadjuvant therapy) in USA (IM) (NCT03262103)
Subscriber content
You need to be a logged in subscriber to view this content.
If your organization
has a subscription
then there are several options available to help you access AdisInsight, even while working remotely.
IP authentication when working within your organization’s network.
Login
with a username/password associated to your organization’s account.
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Federated access using single sign-on credentials.
If your organization
does not have a subscription
to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.
Contact your organization’s admin about adding this content to your AdisInsight subscription
